SmarTrend analyzes over 5,000 stocks simultaneously on an intraday basis using its pattern recognition technology to give you real-time alerts for stocks on the move -- so you can maximize your trading results. Let our system increase your market awareness.
News Watch
- 11/23/2009 1:53:35 PM
By Chip Brian, SmarTrend Analytics Team
11/23/2009 - GlaxoSmithKline (NYSE:GSK) said it's withdrawing its application for U.S. approval of its drug Avodart, according to an AP report. The drug is used for treating symptoms of an enlarged prostate. The company said it wants to provide an update to its application to the FDA and said that its decision is not due to any new findings related to safety or effectiveness of Avodart. Research has shown that Avodart could reduce the risk of prostate cancer by 25%.
Contact Chip Brian
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com. Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at www.TradeTheTrend.com/signup.html
|
